Treatment Strategies and Managing Flares
At a Glance
Treatment for PAPA syndrome is tailored to the active symptoms: short-term steroids may calm joint flares, biologics can reduce ongoing joint or skin inflammation, and dermatology care can treat severe acne. Infection screening and close specialist monitoring are essential.
Managing PAPA syndrome is a balancing act. Because the condition is so rare, there is no universally approved or definitive “one-size-fits-all” treatment sequence. Much of the evidence for treating PAPA consists of case reports and small series with variable responses. Instead, your medical team will tailor your care based on which symptoms are most active at the moment—whether it is joint swelling, skin ulcers, or severe acne [1][2]. This often requires a “trial and adjust” approach, where you and your doctors work together to find the combination of medications that works best for your specific biology.
Addressing Acute Flares
When a joint flare hits, the immediate goal is to reduce pain and inflammation quickly to prevent long-term joint damage. However, infection must always be considered and ruled out before simply suppressing inflammation.
- Corticosteroids: Drugs like prednisone are often used as a defense for an acute joint flare [2]. They work rapidly to “turn off” the intense inflammation. However, they are generally used as a short-term bridge rather than a long-term solution [2]. Never stop taking prolonged steroids abruptly without a doctor’s taper plan, as this can cause a dangerous adrenal crisis.
- The Steroid Trade-off: While effective, using corticosteroids for a long time or in repeated high doses can cause significant side effects, especially in children and teenagers [3]. These risks include:
Because of these risks, your care team will likely introduce steroid-sparing agents—biologic medications designed to manage the disease long-term without the side effects of steroids [2][4].
Targeted Biologic Therapies
Biologics are advanced medications that target specific parts of the immune system. In PAPA syndrome, these are often prescribed off-label. Before starting any biologic, you will need screening for tuberculosis (TB) and hepatitis, a review of your vaccination status (as live vaccines are generally unsafe), and a clear plan on what to do if you develop a fever. Two main “families” of biologics are used [2][1].
IL-1 Inhibitors
Since PAPA syndrome involves an overproduction of the chemical IL-1β, medications that block this signal—such as anakinra or canakinumab—are often used [5][1].
- Best for: While responses vary, these drugs have been used successfully in small series for reducing the number and severity of joint flares [5][4].
- Outcomes: In small studies, some patients on IL-1 inhibitors saw their inflammatory markers (like CRP) return to normal and experienced fewer “sterile” arthritis episodes [5][4].
TNF Inhibitors
Medications like adalimumab, infliximab, or etanercept block a different inflammatory chemical called TNF-alpha [2].
- Best for: While they can help with joints, TNF inhibitors are sometimes favored when pyoderma gangrenosum (the skin ulcers) is the dominant problem [2].
- Note: These medications are not exclusively “joint drugs” or “skin drugs”. Some patients may find that one family of biologics works better for them than the other, and it is not uncommon to switch between them if the first choice doesn’t provide enough relief [4][2].
Managing Severe Acne
The acne in PAPA syndrome is often deep and cystic, requiring more than just standard over-the-counter washes.
- Isotretinoin: This powerful medication is sometimes used for the severe acne associated with PAPA [2]. It can be very effective, but it requires close monitoring by a dermatologist.
- Crucial Safety Warning: Isotretinoin causes severe, life-threatening birth defects (embryofetal toxicity). Strict pregnancy-prevention programs and regular pregnancy testing are mandatory for patients who can become pregnant.
- Safety Monitoring: Because isotretinoin can affect the liver and cholesterol levels, you will need regular blood tests [6]. You should also be monitored for mood or psychiatric symptoms.
- Special Considerations: In some teenagers, starting isotretinoin can occasionally trigger a temporary, severe inflammatory acne flare known as acne fulminans, which requires prompt dermatology review and may require additional steroids to manage [7].
Emerging Options and Combinations
For patients whose symptoms are difficult to control with a single biologic, researchers are exploring new options:
- JAK Inhibitors: Drugs like tofacitinib or baricitinib target a different part of the immune cell’s internal wiring [8][9]. Early reports discuss these drugs in PAPA syndrome [9][8]. However, they carry boxed warnings for serious risks, including severe infections and cardiovascular events.
- Combination Therapy: In very complex cases, some doctors may use a combination of different biologics or a biologic plus a JAK inhibitor [8][10]. Warning: Combining targeted immunosuppressants is generally avoided in routine care because it severely increases the risk of life-threatening infections [10].
These advanced approaches are strictly exceptional, off-label options reserved for highly specialized centers. You should never pursue or combine these powerful medications on your own without a specialist plan and close monitoring. Finding the right strategy takes patience. Your regimen might be a single daily injection, a monthly infusion, or a tailored approach designed to keep both your joints and your skin healthy.
Common questions in this guide
What medicines can calm a PAPA syndrome flare?
Are IL-1 inhibitors or TNF inhibitors better for PAPA syndrome?
What should I check before starting a biologic for PAPA syndrome?
Why do steroids need a taper in PAPA syndrome?
How is severe acne treated in PAPA syndrome?
Are JAK inhibitors or combined biologic treatments used for PAPA syndrome?
Get notified when new evidence is published on PAPA syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (10)
- 1
Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review.
Sanz-Cabanillas JL, Gómez-García F, Gómez-Arias PJ, et al.
Frontiers in immunology 2023; (14()):1339337 doi:10.3389/fimmu.2023.1339337.
PMID: 38259483 - 2
PAPA Syndrome: Challenges in Achieving Long-Term Remission.
Smajlović H, Prohić A
Acta dermatovenerologica Croatica : ADC 2023; (31(2)):106-109.
PMID: 38006373 - 3
A novel de novo PSTPIP1 mutation in a boy with pyogenic arthritis, pyoderma gangrenosum, acne (PAPA) syndrome.
Fathalla BM, Al-Wahadneh AM, Al-Mutawa M, et al.
Clinical and experimental rheumatology 2014; (32(6)):956-8.
PMID: 24960411 - 4
[Targeted therapy of pyogenic sterile arthritis, pyoderma gangrenosum, and acne syndrome (PAPA): a case report and literature review].
Liang WL, Li HG, Zhong G, et al.
Zhonghua er ke za zhi = Chinese journal of pediatrics 2020; (58(12)):977-981 doi:10.3760/cma.j.cn112140-20200430-00456.
PMID: 33256319 - 5
Disease activity accounts for long-term efficacy of IL-1 blockers in pyogenic sterile arthritis pyoderma gangrenosum and severe acne syndrome.
Omenetti A, Carta S, Caorsi R, et al.
Rheumatology (Oxford, England) 2016; (55(7)):1325-35 doi:10.1093/rheumatology/kew031.
PMID: 26989109 - 6
[What's new in clinical dermatology?]
Lok C
Annales de dermatologie et de venereologie 2016; (143 Suppl 3()):S1-S10 doi:10.1016/S0151-9638(18)30043-7.
PMID: 29429503 - 7
Isotretinoin-associated acne fulminans: A multicentre, retrospective study of the European Academy of Dermatology and Venereology Task Force on Acne, Rosacea and Hidradenitis Suppurativa.
Dessinioti C, Dréno B, Bettoli V, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV 2024; (38(1)):197-204 doi:10.1111/jdv.19477.
PMID: 37643921 - 8
Interrupting an IFN-γ-dependent feedback loop in the syndrome of pyogenic arthritis with pyoderma gangrenosum and acne.
Lee W, Stone DL, Hoffmann P, et al.
Annals of the rheumatic diseases 2024; (83(6)):787-798 doi:10.1136/ard-2023-225085.
PMID: 38408849 - 9
A protracted diagnostic journey of pediatric PAPA syndrome and subsequent response to tofacitinib therapy: a case report and literature review.
He S, Deng H, Yang J, Jiang W
Frontiers in immunology 2026; (17()):1870454 doi:10.3389/fimmu.2026.1870454.
PMID: 42682796 - 10
Biologic-biologic and biologic-JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases.
Tufan A, Stone DL, Romeo T, et al.
Seminars in arthritis and rheumatism 2026; (80()):153067 doi:10.1016/j.semarthrit.2026.153067.
PMID: 42691741
This page is for informational purposes only and does not constitute medical advice. Your rheumatologist and dermatologist should guide medication choices, infection screening, and steroid tapering for PAPA syndrome.